- ►prsjournal.com AL Takeda, J Colquitt, AJ Clegg, J Jones - British Journal of Ophthalmology, 2007 - bjo.bmj.com Results: Three RCTs of ranibizumab (MARINA, ANCHOR, FOCUS) and two of pegaptanib (VISION
study) met the inclusion criteria. The RCTs included patients with different lesion types. The studies
showed statistically significant benefit on different measures of visual acuity for patients ... Cited by 37 - Related articles - BL Direct - All 6 versions
J Bradley, M Ju, GS Robinson - Angiogenesis, 2007 - Springer Abstract The growth of inappropriately regulated, leaky blood vessels is a prominent component
of sev- eral debilitating eye diseases, such as age-related macular degeneration (AMD), proliferative
diabetic retinopathy (PDR), and retinopathy of prematurity (ROP). New pharmacological ... Cited by 37 - Related articles - BL Direct - All 3 versions
- ►iovs.org BR Mwaikambo, F Sennlaub, H Ong, S Chemtob, P … - … ophthalmology & visual …, 2006 - ARVO METHODS. In a murine model of inflammatory CNV, CD36 expression was evaluated by
RT-PCR and immunofluorescence. Mice subjected to CNV were treated topically (thrice
daily) with CD36 functionally neutralizing antibodies against the oxidized low-density ... Cited by 18 - Related articles - BL Direct - All 3 versions
B Desvergne - Nature medicine, 2007 - nature.com Jump to main content; Jump to navigation; nature.com homepage; Publications AZ index;
Browse by subject. My account; Submit manuscript; Register; Subscribe. Advertisement.
Login. Nature Medicine homepage Search This journal. ... Cited by 5 - Related articles - BL Direct - All 5 versions
J Adamkiewicz, K Kaddatz, M Rieck, B Wilke, S Müller- … - Proteomics, 2007 - imt.uni-marburg.de The peroxisome proliferator activated receptor-b (PPARb) plays an essential role in lipid
metab- olism, immune modulation, differentiation and cell proliferation. There is also strong evidence
for a function in oncogenesis and tumor vascularization, but the underlying molecular ... Cited by 9 - Related articles - View as HTML - BL Direct - All 6 versions
AAOFO AAO - clienti.tio.ch Jeffrey Heier (Department of Ophthalmology, Harvard Medical School, Boston, MA, USA) presented
updated findings from the ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly
Classic Choroidal Neo- vascularisation in Age-Related Macular Degeneration) study. ... Related articles - View as HTML
- ►prsjournal.com UM Schmidt-Erfurth, G Richard, A Augustin, … - Acta Ophthalmologica …, 2007 - pt.wkhealth.com Neovascular age-related macular degeneration is becoming an increasing socio-medical problem
as the proportion of the aged population is continuously increasing. However, new insights in
the pathogenesis of the disease offer the opportunity to develop targeted therapies that ... Cited by 28 - Related articles - BL Direct - All 8 versions
RP Singh - members.medscape.com Jason Slakter [1] presented 1-year optical coherence tomographic (OCT) and fluorescein angiographic
results from the CLEAR-IT 2 trial -- a double-masked, multicenter, phase 2 trial that is examining
the use of intravitreal VEGF Trap for neovascular AMD. A total of 157 patients received ... Cited by 1 - Related articles - All 2 versions
JI Lim - jhasio.com Over the past decade, treatment of neovascular age-related macular degeneration has evolved
from overall retinal ablation to more targeted and retinal-sparing therapy, beginning with the
advent of photodynamic therapy and continuing with the development of inhibitors to ... Related articles
- ►medscape.com CME Tracker - medscape.com Ever since the initial results showing visual acuity gains with the use of the anti-vascular endothelial
growth factor (VEGF) agent ranibizumab for age-related macular degeneration were
presented, the retinal community has been abuzz with news of anti-VEGFs. Should ... Related articles - All 5 versions
